TCS 183

TCS 183, a peptide, is a GSK-3β inhibitor. TCS 183 blocks GSK-3β autoinhibition and decreases the level of AMPK phosphorylation. TCS 183 can be used for neuropathological diseases, particularly Alzheimer’s disease, research[1].

Product Specifications

UNSPSC

12352209

Target

GSK-3; p38 MAPK

Related Pathways

MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Neurological Disease

Smiles

O=C(N[C@@H](CO)C(NCC(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCSC)N

Molecular Formula

C58H96N20O20S

Molecular Weight

1425.57

References & Citations

[1]Ríos JA, et al. Wnt3a ligand facilitates autophagy in hippocampal neurons by modulating a novel GSK-3β-AMPK axis. Cell Commun Signal. 2018 Apr 11;16 (1) :15.